Functional outcomes, feasibility, and safety of resection of transoral robotic surgery: Single-institution series of 35 consecutive cases of transoral robotic surgery for oropharyngeal squamous cell carcinoma
Functional outcomes, feasibility, and safety of resection of transoral robotic surgery: Single-institution series of 35 consecutive cases of transoral robotic surgery for oropharyngeal squamous cell carcinoma
复制标题
DOI：
10.1002/hed.23809
复制
发表时间：
2015-11-01
影响因子：
2.9
通讯作者：
Knecht, Rainald
中科院分区：
文献类型：
--
作者：
Loerincz, Balazs B.;Moeckelmann, Nikolaus;Knecht, Rainald
背景资料。这是一项在三级护理中心进行的单机构前瞻性研究，旨在评估口咽鳞状细胞癌(SCC)经口腔机器人辅助切除的可行性、切除的完全性和功能结果。研究对象为口咽部T1、T2鳞癌患者35例。他们在2011年9月至2013年4月期间接受了经口腔机器人手术(TORS)，平均随访时间为13个月。术后出血、插管天数、择期气管切开率、重症监护和/或中期监护时间、言语和吞咽功能、鼻胃和/或胃造瘘管依赖长度为主要观察指标。我们对35例主要接受Tors治疗的口咽癌患者的1年(中位数)功能和早期肿瘤学结果是鼓舞人心的，在选定的亚组患者中继续获得这种手术方式的进一步经验。(C)2014年威利期刊公司。
Background. This is a single-institution prospective study in a tertiary care center to evaluate feasibility, completeness of resection, and functional outcomes for oropharyngeal squamous cell carcinoma (SCC) treated primarily with transoral robotic-assisted resection.Methods. Thirty-five patients with T1 and T2 squamous cell carcinoma of the oropharynx were included. They underwent transoral robotic surgery (TORS) between September 2011 and April 2013, with a median follow-up time of 13 months.Results. Main outcome measures were completeness of resection, disease-free survival, and cancer recurrence for the preliminary oncologic outcome; postoperative bleeding, number of days intubated, rate of elective tracheotomy, duration of intensive care and/or intermediate care, speech and swallowing function, and length of nasogastric and/or gastrostomy tube dependency for the functional results.Conclusion. Our 1-year (median) functional and early oncologic results of 35 patients with oropharyngeal cancer treated primarily with TORS are encouraging to continue gaining further experiences with this surgical modality on a select subgroup of patients. (C) 2014 Wiley Periodicals, Inc.